

KNOWLEDGE SHARING AND CAPACITY BUILDING

- There is *no “one size fits all” approach* for CGT products given the broad diversity of modalities and corresponding properties.
- Developing CGTP for ultra/rare diseases has many challenges. The cost of manufacturing AAV GT is extremely high. There is a *call for CMC expertise to drive down the cost of production.*
- Cellular starting materials (CSM) need to be characterized and, to the extent possible, their variability understood and taken into account when the sponsor sets specifications and conducts comparability assessments. We are *beginning to see developers undertake the complex task of characterizing CSM.*

Cell & Gene Therapy Products 2023 BY THE NUMBERS



**Attendee
Participants**
In-Person - **256**
Virtual - **147**
First Time - **165**



**Regulators
Participation**
39



**Company
Participation**
135



Country Participation
20

Afghanistan | Austria | Belgium | Canada | China | Denmark |
Finland | France | Germany | Ireland | Israel | Italy |
Netherlands | Portugal | Singapore | South Korea | Spain |
Switzerland | United Kingdom | United States